Position in NUVB
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$8,561,797
-$6,393,927 QoQ
Shares Held
1,995,758
+19.6% QoQ
Ownership
0.573%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 96%
Shared 0%
None 4%
Common Shares in NUVB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026AQR CAPITAL MANAGEMENT LLC holds $4,606,751,734 across 214 Biotechnology names. NUVB ranks #45 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,231,008 | $951,126,014 | |
| 2 | EXEL |
Exelixis, Inc.
|
13,095,741 | $561,676,326 | |
| 3 | INCY |
Incyte Corp
|
5,807,930 | $546,642,368 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
7,676,541 | $433,647,798 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
913,104 | $302,118,715 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
1,338,458 | $253,035,481 | |
| 7 | RPRX |
Royalty Pharma plc
|
3,782,038 | $181,424,357 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
5,946,858 | $164,727,963 |
All Filings in NUVB
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $8,561,797 | 1,995,758 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $14,955,724 | 1,669,166 | Shares | Other | 2026-02-17 | |
| 2025-09-30 | $7,526,579 | 2,034,211 | Shares | Other | 2025-11-14 | |
| 2025-06-30 | $2,217,718 | 1,137,292 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $238,318 | 135,409 | Shares | Other | 2025-05-15 | |
| 2024-12-31 | $2,184,814 | 821,359 | Shares | Other | 2025-02-14 | |
| 2024-09-30 | $1,700,180 | 742,437 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $325,821 | 111,583 | Shares | Other | 2024-08-14 | |
| 2024-03-31 | $66,793 | 18,350 | Shares | Other | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||